Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Non-Current Assets (2018 - 2025)

10x Genomics' Non-Current Assets history spans 8 years, with the latest figure at $356.9 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 6.78% year-over-year to $356.9 million; the TTM value through Dec 2025 reached $1.4 billion, down 0.87%, while the annual FY2025 figure was $356.9 million, 6.78% up from the prior year.
  • Non-Current Assets for Q4 2025 was $356.9 million at 10x Genomics, down from $367.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $412.1 million in Q1 2023 and bottomed at $208.3 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $347.2 million (2024), against an average of $334.0 million.
  • The largest annual shift saw Non-Current Assets soared 75.02% in 2021 before it dropped 13.81% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $271.2 million in 2021, then surged by 45.24% to $393.9 million in 2022, then fell by 6.3% to $369.1 million in 2023, then fell by 9.45% to $334.2 million in 2024, then grew by 6.78% to $356.9 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Non-Current Assets are $356.9 million (Q4 2025), $367.5 million (Q3 2025), and $324.3 million (Q2 2025).